OBJECTIVE: Elevated levels of fetal cell free DNA (cfDNA) in maternal circulation have been observed in pathologic conditions such as preeclampsia and preterm birth at the time of diagnosis. Evidence is conflicting, however, on the clinical significance of a high fetal fraction (FF) result on routine aneuploidy screening. We aimed to test the hypothesis that high FF is associated with adverse perinatal outcomes in women with an otherwise normal first trimester cfDNA result. STUDY DESIGN: This is a single-institution retrospective cohort study of women who underwent cfDNA aneuploidy screening at <14 weeks' gestation and delivered a viable infant between July 2016 and June 2018. Women with a multiple gestation, abnormal cfDNA result, or low fetal fraction (<5%ile) were excluded. The primary outcome of interest was preterm birth <37 weeks' gestation; secondary outcomes were hypertensive disorders of pregnancy, low birth weight 10%ile and 5%ile using growth curves by Oken et al., and abruption. High FF was defined as >95%ile. RESULTS: Of 1,933 women that met inclusion criteria, the mean FF was 10.4%, and a FF >16.5% was considered high (n¼101). Median maternal age of the study population was 36, consistent with indication for aneuploidy screening. Compared to women with normal FF, women with high FF had significantly lower BMI (21.6 vs 24.1 kg/m 2 , P<0.001) and were more likely to be multiparous (43% vs 29%, P<0.01). We found no significant difference in the rate of preterm birth <37 weeks' gestation between groups, though results were limited by sample size. However, women with high FF were more likely to have a low birth weight infant 5%ile (OR 2.4[1.1-5.4]), which maintained significance after controlling for gestational age at the time of cfDNA testing, BMI, maternal age, and parity. High FF was also associated with low birth weight 10%ile (OR 1.9[1.1-3.5]), though this result did not maintain significance after controlling for confounders. There was no significant difference in rates of abruption or hypertensive disorders of pregnancy between groups. CONCLUSION: High FF in the first trimester is associated with low birth weight infants in patients with otherwise negative aneuploidy screening results. Further investigation into the clinical implications of a high FF result is warranted.
902 Cell-free DNA for Down syndrome screening in morbidly obese women: Is it a cost-effective strategy? OBJECTIVE: Cell-free DNA (CfDNA) screening in morbidly obese (body mass index 40 kg/m2) women has an increased no result rate due to lower fetal fraction. Conventional serum screening is not limited by maternal weight. The aim of this project was to estimate the costeffectiveness of trisomy 21 (T21) screening in morbidly obese women using cfDNA compared to traditional serum integrated screening. STUDY DESIGN: Using TreeAge software, we created a decision-analytic model to compare two prenatal screening strategies for fetal trisomy 21 detection: (1) Serum integrated screening (INT) with first trimester PAPP-A and beta-hCG and second trimester quad screen and (2) cfDNA screening. We performed a literature review to model rates of insufficient fetal fraction, invasive testing for abnormal results, test performance characteristics, incidence of T21, rates of live birth, termination, and stillbirth in each clinical scenario. Costs of screening, invasive testing, termination, procedurerelated fetal loss and of a T21 live birth were obtained from literature review. Primary outcomes of the model were the cost of each strategy, number of unnecessary invasive tests, procedure-related fetal losses, and missed cases of T21. RESULTS: In the base case, the mean cost of cfDNA was $453 greater than that of INT ($1,310 vs $857). cfDNA resulted in a lower probability of an unnecessary invasive test (2.9% vs 3.7%), procedurerelated fetal loss (0.015% vs 0.019%), and missed cases of T21 (0.00013% vs 0.02%), respectively. cfDNA cost $56,000 per unnecessary invasive test avoided, $11 million per procedure-related fetal loss avoided, and $2 million per missed case of T21 avoided. In sensitivity analysis, when the probability of an insufficient fetal fraction is assumed to be > 25%, cfDNA is both costlier than INT and results in more unnecessary invasive testing (a dominant strategy). CONCLUSION: When compared to serum integrated screening, cfDNA is costlier and results in higher rates of unnecessary invasive testing in morbidly obese women with a probability of insufficient fetal fraction > 25%, which occurs at a maternal weight of approximately 300 pounds.
903 Cell-free DNA fetal fraction and risk for gestational diabetes OBJECTIVE: Previous studies have suggested a relationship between a low fetal fraction of cell-free DNA (cfDNA) and gestational diabetes (GDM). The aim of this study was to determine the association between cfDNA fetal fraction and GDM in a cohort of patients presenting for cfDNA screening for fetal aneuploidy. STUDY DESIGN: Retrospective cohort study of women with singleton pregnancies who had cfDNA screening at a single institution at 10-20 weeks gestation between October 2011 and October 2017. GDM was defined using the Carpenter-Coustan criteria. Cases with fetal aneuploidy, stillbirth and unavailable outcome were excluded. Fetal fractions were adjusted for gestational age using multiples of the median. Multivariable logistic regression was used to estimate the odds ratio (OR) of GDM controlling for potential confounders. RESULTS: Among 2,623 pregnancies meeting inclusion criteria, 150 (5.7%) were diagnosed with GDM. Demographic characteristics were similar between the two groups ( Table 1 ). The mean gestational age and maternal age at the time of cfDNA screening were 12.8 weeks and 39.1 years, respectively. GDM was associated with increased BMI and older maternal age. Women with GDM had a lower fetal fraction (0.93 MoM v. 1.05 MoM, p ¼ 0.002). However, the association between fetal fraction and GDM was not significant after adjusting for BMI (OR 0.84, 95% CI 0.52-1.36; p¼0.475) ( Table 2 ). Since insulin resistance increases at later gestational ages, a separate analysis on women with gestational age 14-20 weeks at the time cfDNA screening was performed. Again, the association between fetal fraction and GDM was not significant after adjusting for BMI (OR 0.81, 95% CI 0.31-2.12; p¼0.672). CONCLUSION: In this large retrospective cohort study, low cfDNA fetal fraction at 10-20 weeks gestation was not associated with the development of GDM. Although fetal fraction was lower among women diagnosed with GDM, this relationship was no longer statistically significant once maternal BMI was taken into account.
